Leerink Partnrs lowered shares of 908 Devices (NASDAQ:MASS – Free Report) from a strong-buy rating to a hold rating in a research report released on Wednesday,Zacks.com reports.
Several other research analysts have also weighed in on the stock. Leerink Partners restated a “market perform” rating and set a $4.00 target price (down from $12.00) on shares of 908 Devices in a research report on Wednesday. Stifel Nicolaus dropped their price objective on 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday.
Read Our Latest Analysis on MASS
908 Devices Stock Down 19.9 %
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in MASS. SG Americas Securities LLC purchased a new stake in shares of 908 Devices in the third quarter valued at $36,000. GAMMA Investing LLC purchased a new position in shares of 908 Devices during the 2nd quarter worth about $48,000. Drive Wealth Management LLC acquired a new stake in shares of 908 Devices in the third quarter worth approximately $50,000. Townsquare Capital LLC acquired a new position in 908 Devices during the third quarter worth approximately $50,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in 908 Devices during the first quarter worth approximately $80,000. Institutional investors and hedge funds own 88.06% of the company’s stock.
908 Devices Company Profile
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
See Also
- Five stocks we like better than 908 Devices
- Most active stocks: Dollar volume vs share volume
- Top 3 R&D-Driven Stocks Showing Strong Profit and Momentum
- Financial Services Stocks Investing
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Tariff Troubles: 3 Stocks Planning Higher Prices
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.